REG - N4 Pharma PLC - Posting of Annual Report and Notice of AGM

N4 PharmaAnnouncement

22/05/2019 07:00

For best results when printing this announcement, please click on link below:
http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20190522:nRSV7464Za

RNS Number : 7464Z
N4 Pharma PLC
22 May 2019
 
22 May 2019
N4 Pharma Plc
("N4 Pharma" or the "Company")
 
Posting of Annual Report and Notice of AGM
 
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec®, a novel delivery system for vaccines and cancer
treatments, announces that its Annual Report and Accounts for the year ended
31 December 2018 and Notice of the Annual General Meeting will be posted to
shareholders later today, and are available on the Company's website at
https://www.n4pharma.com (https://www.n4pharma.com/) .
 
The Company's Annual General Meeting will be held at 11.00 a.m. on 19 June
2019 at the offices of Allenby Capital Limited, 5 St Helen's Place, London
EC3A 6AB.
 
For further information please contact:
 
Enquiries:
 
 N4 Pharma Plc
 Nigel Theobald, CEO       Via Scott PR
 Allenby Capital Limited   Tel: +44(0)203 328 5656
 James Reeve/Asha Chotai
 Scott PR
 Georgia Smith             Tel: +44(0)1477 539 539
 
About N4 Pharma
 
N4 Pharma is a specialist pharmaceutical company developing a novel delivery
system for vaccines and cancer treatments using its unique silica nanoparticle
delivery system called Nuvec®.
 
N4 Pharma's business model is to partner with companies developing novel
antigens for vaccines and cancer treatments to use Nuvec® as the delivery
vehicle to get their antigen into cells to express the protein needed for the
required immunity. As these products progress through pre clinical and
clinical programs, N4 Pharma will seek to receive up front payments, milestone
payments and ultimately royalty payments once products reach the market.
 
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.